Participants are placed by chance into one of the study groups and neither the study team nor the family knows which treatment is being given. The study medicine or placebo is added to the usual care already being used for this serious condition. The trial is designed to look at both the benefits and the safety of the treatment during the first hours and days after it is started.

In this study, participants will receive either vasopressin or a placebo in addition to their standard treatment, which includes a medication called noradrenaline. Noradrenaline is commonly used to help maintain blood pressure in patients with septic shock. The study will compare the effects of vasopressin with those of a placebo to see if there is a difference in how well the organs function after treatment. The treatment will be administered through an intravenous infusion, which means it will be given directly into the bloodstream over a period of time.

The study will last for a maximum of five days, during which the health of the participants will be closely monitored. Researchers will look at various health indicators, such as changes in organ function and overall survival rates, to determine the effectiveness of the treatment. The goal is to gather information that could lead to improved treatment options for patients with septic shock in the future.

The purpose of the study is to evaluate whether the infusion of human serum albumin can help prevent severe AKI in these patients during the first week after the onset of septic shock. Participants in the study will receive either the human serum albumin treatment or a placebo. The study will monitor the participants’ kidney function and overall health for several weeks to assess the treatment’s effectiveness and safety.

Throughout the study, researchers will also track other health outcomes, such as the need for additional organ support, the length of time patients require treatments like mechanical ventilation, and overall survival rates over a 28-day period. The study aims to provide valuable insights into whether human serum albumin can improve outcomes for patients with septic shock and a high risk of AKI.

Two different solutions for infusion will be used in this study. One is called Suero Fisiológico Vitulia 0.9% solution for infusion, which contains sodium chloride, a common salt used to help maintain fluid balance in the body. The other is Lactato Ringer Braun solution for infusion, which contains a mix of potassium chloride, sodium chloride, calcium chloride dihydrate, and sodium lactate. These substances are used to help restore the balance of electrolytes, which are minerals in the body that carry an electric charge and are essential for many bodily functions.

The purpose of the study is to determine if this new treatment approach can improve outcomes for patients with septic shock, such as reducing the risk of death, shortening the time patients need vital support, and decreasing the length of hospital stay, all within 28 days. Participants in the study will receive either the new treatment approach or the usual care, and their progress will be monitored over this period. The study will help to understand if this new method can provide better results compared to the standard treatment currently used for septic shock.

The purpose of the study is to determine how MSCs affect the progression of organ failure in patients with septic shock. Participants in the study will receive the treatment within 12 hours of the onset of septic shock. The study will monitor the patients’ health over a period of time to assess the impact of the treatment on their condition. The main focus will be on the Sepsis Organ Failure Assessment (SOFA) score, which is a measure used to track a patient’s status during treatment. The study will also look at other factors, such as the number of days patients can live without needing respiratory support or other intensive care interventions.

Throughout the study, researchers will observe any changes in the patients’ health, including potential side effects or improvements. The study aims to provide valuable information on whether MSCs can be an effective treatment for reducing organ failure in septic shock patients. This research could lead to new ways to help patients recover from this life-threatening condition.

Participants in the study will receive either ivabradine or a placebo, which looks like the real medication but does not contain any active ingredients. The study will be conducted in two stages. The first stage will focus on how well ivabradine controls heart rate, while the second stage will assess its impact on survival rates. The trial will also look at how well patients tolerate ivabradine and its effects on heart function, organ health, and overall recovery in intensive care.

The study will last for a period of time, during which participants will be monitored closely to track their heart rate and overall health. The goal is to determine if ivabradine can be an effective treatment for managing heart rate and improving outcomes in patients with septic shock. This research could provide valuable insights into better treatment options for this serious condition.

Participants in the study will receive either nicotinamide or a placebo. The treatment will be administered through an injection into the vein. The study will monitor the patients over a period of time to see if nicotinamide is more effective than the placebo in reducing the risk of major kidney events. These events include in-hospital mortality, the need for new renal replacement therapy, or ongoing kidney dysfunction.

The study will also look at other factors such as the length of hospital stay, the number of days patients live without needing kidney support, and any potential side effects like liver toxicity, nausea, or headaches. The goal is to gather information on whether nicotinamide can improve outcomes for patients with septic shock and reduce the incidence of kidney-related complications.

Participants in the study will receive either the medication epirubicin or a placebo. Epirubicin is administered as a solution for injection, and it is typically used in cancer treatment. In this study, it is being tested for its potential benefits in treating sepsis and septic shock. The study will also use a solution called sodium chloride, commonly known as saline, which is often used in medical settings to provide fluids and electrolytes to patients.

The purpose of the study is to determine if low-dose epirubicin is safe for patients with sepsis and septic shock. Participants will be monitored for safety, including any potential side effects, over a period of time. The study will also look at how the treatment affects organ function and overall survival rates. The trial is expected to continue until 2025, with the goal of providing valuable information on the use of epirubicin in treating these serious conditions.

The study will compare two groups of patients – one receiving levetiracetam and another receiving placebo through an infusion into their veins. The medication or placebo will be given for seven days. The main goal is to determine if levetiracetam can increase the number of days that patients remain alert and free from confusion during their first two weeks of treatment.

Patients will be monitored for various outcomes, including their mental state, need for breathing support, and overall recovery. The study will also track long-term effects by following up with patients after three months to assess their thinking abilities, emotional well-being, and ability to perform daily activities. The treatment involves receiving either levetiracetam (up to 2000 mg per day) or sodium chloride solution as the placebo.

The purpose of the study is to determine if a personalized dose of this treatment, based on the levels of immunoglobulin M in the blood, is more effective in reducing the risk of death in patients with septic shock compared to a standard dose. Participants in the study will receive either the personalized dose or the standard dose of Pentaglobin. The study will monitor the participants over a period of time to assess the outcomes, including survival rates and any new organ dysfunctions.

The study is designed to be adaptive, meaning it can adjust based on the results as it progresses. It is conducted in a way that neither the participants nor the researchers know which dose each participant is receiving, ensuring unbiased results. The main goal is to see if the personalized dosing approach can improve survival rates at 28 days after treatment begins. The study will also look at other factors, such as recovery and any side effects related to the treatment.

Participants in the study will receive either sodium lactate or 3% saline solution, and the effects on their heart function and blood pressure will be monitored. The study will observe changes in the heart’s ability to pump blood and the stability of blood pressure at different times after the treatment begins. Additionally, the study will compare certain blood test results between the two groups to understand how each treatment affects the body’s balance of acids and bases, as well as electrolytes, which are minerals in the blood that help with various bodily functions.

This trial is designed to be double-blinded, meaning neither the participants nor the researchers know which treatment is being given to each participant, to ensure unbiased results. The study aims to provide valuable information on the best way to manage fluid resuscitation in septic shock, potentially improving treatment outcomes for patients with this life-threatening condition.

Participants in the study will receive either vasopressin and norepinephrine together or norepinephrine alone initially, with vasopressin added later if needed. The study will monitor how these treatments affect the need for kidney support, such as dialysis, and other health outcomes. The medications used in this study include SonoVue, which contains sulfur hexafluoride, and Empressin, which contains argipressin. These medications are administered intravenously, meaning they are given directly into a vein.

The study will also look at other factors, such as how well blood flows to the kidneys, the balance of fluids in the body, and any side effects like heart rhythm problems or reduced blood flow to the intestines or limbs. The goal is to see if early use of vasopressin can lead to better outcomes for patients with septic shock, including shorter stays in the ICU and improved survival rates. The study is expected to continue until March 2026.

The purpose of the study is to assess how these treatments affect the survival and other important health outcomes of critically ill adults with sepsis. Participants in the study will receive either Meropenem or Piperacillin/Tazobactam, and their health will be monitored over a period of time to see how they respond to the treatment. The study will look at various outcomes, including the number of days patients are alive without needing life support, the number of days they spend out of the hospital, and their overall quality of life.

The trial will also track any serious side effects that may occur, such as allergic reactions or infections, and will evaluate the presence of any resistant bacteria. The study aims to provide valuable information on which treatment may be more effective for patients with sepsis, ultimately helping to improve care for those affected by this life-threatening condition.

The purpose of the study is to compare the survival rates over 28 days between patients receiving L-Carnitine and those who do not. Participants in the study will be randomly assigned to one of two groups: one group will receive L-Carnitine along with their standard treatment, while the other group will receive the standard treatment without L-Carnitine. Some participants may receive a placebo instead of L-Carnitine. The study will monitor various health outcomes, such as the number of days patients are alive without needing kidney support, mechanical ventilation, or intensive care.

The study will last for a period of time, during which participants will be closely monitored by healthcare professionals. The goal is to determine if adding L-Carnitine to the treatment plan can help improve survival and recovery in patients with septic shock and acute kidney injury. This research could provide valuable insights into better treatment options for these serious conditions.

Participants in the study will receive the treatment through an intravenous infusion, which means it will be administered directly into the bloodstream. The study will monitor changes in the health of several organs, including the lungs, heart, kidneys, liver, and blood, over a period of seven days after the infection source has been controlled. The goal is to see if Pentaglobin can help reduce the severity of multiple organ failure, a condition where several organs stop working properly, which can occur in severe cases of peritonitis and sepsis.

The study will also track other important outcomes, such as survival rates within 28 and 90 days, and changes in the severity of organ failure by the fifth day of treatment. By understanding these effects, researchers hope to determine the potential benefits of using Pentaglobin in treating these serious conditions. The study is designed to provide valuable insights into personalized medicine approaches for patients with peritonitis and sepsis.

The purpose of the study is to see if adding terlipressin to noradrenaline can help reduce organ failure and increase the number of days patients can spend outside of the intensive care unit (ICU) within 28 days. Participants will be randomly assigned to one of the two treatment groups, and neither the participants nor the researchers will know which treatment each participant is receiving. This is known as a “double-blind” study, which helps ensure the results are not biased.

Throughout the study, researchers will monitor the participants’ health, focusing on how well their organs are functioning and how many days they can spend without needing intensive care. The study will also look at other factors, such as the clearance of lactate (a substance that can build up in the blood during severe illness), the number of days without needing mechanical ventilation, and the overall survival rate. The study aims to provide valuable information on whether the combination of noradrenaline and terlipressin is more effective than noradrenaline alone in treating septic shock.

Participants in the study will receive either the landiolol treatment or the standard care, which may include a placebo. The study will monitor patients over a period of 28 days to assess the impact of the treatment on their survival. During this time, researchers will also observe other factors such as the number of days patients need medications to support their heart, the length of time they require mechanical breathing support, and their overall stay in the hospital.

The study aims to provide valuable insights into whether landiolol can be an effective treatment option for patients with septic shock. By comparing the outcomes of those receiving landiolol with those receiving standard care, the study hopes to determine if this medication can help reduce the risk of death in these critically ill patients.